Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli via the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback